Showing posts with label Par. Show all posts
Showing posts with label Par. Show all posts

Wednesday, October 23, 2013

Horizon, Par Resolve Patents Suits over Duexis Generic

Case Closed: Oct 17, 2013

Court: Delaware District Court

Judge: Leonard P. Stark

Case Summary:
Par resolved suits brought in by Horizon accusing the generic manufacturer of infringing its patents relating to treating arthritis. Judge granted the stipulation filed by the parties and dismissed the cases without prejudice, ending the litigations over Horizon’s abbreviated new drug application for a generic version of Duexis® infringing the ‘127, ‘202 and ‘033 patents covering the medication.

It appears that the Parties entered into settlement with licensing agreements, and Horizon has granted Par the non-exclusive right to market a generic ibuprofen and famotidine product in the US under Par's Abbreviated New Drug Application (ANDA), beginning January 1, 2023, or earlier under certain circumstances. Other details of the settlement were not disclosed.

Horizon filed complaints to protect three of its patents after Par submitted an ANDA no. 203658 to the U.S. Food and Drug Administration (FDA) for tablets containing 800 mg of ibuprofen and 26.6 mg of famotidine as active ingredients (a generic version of Duexis) by which it alleged that Par had committed an act of infringement. The court document said, unless a judge stops the alleged infringement, “Horizon will be irreparably harmed”. Horizon sought the court to declare a permanent enjoinment of Par from marketing and selling its generic version of Lotrel, as well as a court order that any approval of Par’s ANDA would not be effective until after expiration of the ‘127, ‘202 and ‘033 patents.

The patents in suits were: US8309127, US8318202 and US8067033 all entitled Stable compositions of famotidine and ibuprofen were issued on Nov 13, 2012, Nov 27, 2012 and Nov 29, 2011, respectively. The patents expire[*] by Nov 26, 2028 and are assigned to Horizon Pharma as per face page. As per the complaints, the ‘127 patent covers the Duexis® product and the '033 and '202 patent discloses a composition containing famotidine and ibuprofen.

Horizon’s Duexis is a combination drug used to treat signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers. Horizon currently holds[†] the new drug application no. 022519 for tablets, which contains 26.6 mg of famotidine and 800 mg of ibuprofen as active ingredients, which it sells under the brand name Duexis® (source: MaxVal’s Patent Marker) and approved by FDA on Apr 23, 2011.

See cases 1:13-cv-00102 and 1:12-cv-00393 for more details. To get alerts on cases filed/closed, subscribe to our Litigation Alerts.

Are you looking for a tool to calculate patent terms? Try Patent Term Estimator, our free tool or download our free Android app on Google Play Store.




[*] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
[†] Patent Marker provides an online environment where patentees can virtually mark products and search products for patent-related information.

Sunday, September 29, 2013

Purdue, Par Conclude Lawsuit over Generic OxyContin

Case Filed: Mar 23, 2011

Case Closed: Sep 24, 2013

Court: New York Southern District Court

Judge: Sidney H. Stein

Case Summary:
A patent infringement suit was filed by Purdue, Grunenthal and Texas System against Par as a result of the latter’s filing of an abbreviated new drug application (ANDA) with FDA concerning their intent to market a generic version of OxyContin, used to treat moderate to severe pain. The patents involved in the suit are:

Patent Number
Current Assignee[i]
Issued Date
Expiration Date[ii]
Title
US7674799
Mar 09, 2010
Mar 30, 2025
Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US7674800
Mar 09, 2010
Mar 30, 2025
Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
US7683072
Mar 23, 2010
Mar 30, 2025
Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
US6488963
Dec 03, 2002
Mar 02, 2019
Hot-melt extrudable pharmaceutical formulation
US7776314
Aug 17, 2010
Jun 17, 2022
Abuse-proofed dosage system
Current Assignee sourced from MaxVal’s Assignment Database.

Purdue alleged that Par’s abbreviated new drug application no. 202434 with FDA seeking approval to engage in commercial manufacturing of the drug containing oxycodone hydrochloride extended release tablets has infringed the above said patents, all of which cover the composition of the drug.

Purdue currently holds new drug application (NDA) no. 022272 for controlled-release oxycodone pain-relief medication OxyContin approved by FDA on April 5, 2010. It is indicated for the management of moderate to severe pain when a continuous, round-the-clock opioid analgesic is needed for an extended period of time. Plaintiffs wanted judgment that defendant has infringed the patents and an injunction barring their products until expiration of the patents, along with costs and expenses.

The parties reached a settlement on Sep 20, 2013. Pursuant to the terms of settlement, it was agreed that:
  •        5 of the patents-in-suit are valid and enforceable and Par’s ANDA would infringe the patents
  •         Par’s product will be enjoined from infringing until the expiration date

The Court signed off a consent judgment ordering dismissal without prejudice with no charges imposed on any parties.  

See 1:11-cv-02038 for more details. To get alerts on cases filed/closed, subscribe to our Litigation Alerts.

Has this patent been litigated? Use our free tool or download our free Android/iOS app on Google Play/ App Store.



[i] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded. 
[ii] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.

Wednesday, May 29, 2013

Galderma Settles Generic Epiduo Patent Suit with Par Pharmaceutical

Galderma Laboratories filed a lawsuit in the Northern District of Texas against Watson Pharmaceuticals.  Watson submitted an ANDA (abbreviated new drug application) no. 204067 seeking approval to engage in the commercial manufacture of generic Adapalene and Benzoyl Peroxide Gel, which according to Galderma infringes the claims of three of its patents. The patents involved in this suit were:

US8071644 - Combinations of adapalene and benzoyl peroxide for treating acne lesions and issued on Dec 06, 011.
US8080537 - Combinations of adapalene and benzoyl peroxide for treating acne lesions and issued on Dec 20, 2011
US8129362 - Combination/association of adapalene and benzoyl peroxide for treating acne lesions and issued on Mar 06, 2012

The patents expire[i] by Jul 13, 2026 and are currently assigned[ii] to Galderma (source: MaxVal’s Assignment Database). Galderma currently holds[iii] the NDA (new drug abbreviation) no. 022320 for Epiduo® gel to treat acne (source: MaxVal’s Patent Marker) approved by FDA in Dec, 2008. 

Par Pharmaceuticals substituted Watson during the prosecution. The case is now closed as the parties have filed for stipulated dismissal and the Court ordered dismissal upon the request. However, no further information is available on the terms of settlement.

Case Filed: Jul 27, 2012

Case Closed: May 21, 2013

Judge: Ed Kinkeade

Court: Texas Northern District Court

See 3:12-cv-02563 for more details. To get alerts on cases filed/closed, subscribe to our Litigation Alerts.
Has this patent been litigated? Use our free tool or download our free Android/iOS app on Google Play/ App Store.



[i] Expected expiration date. Patent Term Estimator is a free web-based tool that automatically calculates patent terms and expiration dates for U.S. utility patents.
[ii] MaxVal offers Patent Assignment Alert service where subscribers receive email alerts when assignments relating to target applications, patents or entities of interest are recorded.
[iii] Patent Marker provides an online environment where patentees can virtually mark products and search products for patent-related information.